PCAS and Nanosyn have signed a joint-venture agreement to operate PCAS-Nanosyn, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California.
The newly created company, PCAS-Nanosyn will enable PCAS and Nanosyn to satisfy a broader range of customer needs in the pharmaceutical and biotech marketplaces by offering fully integrated custom chemical services, from discovery to commercialisation.
Reportedly, the joint venture operation, PCAS-Nanosyn will provide services out of an FDA inspected facility in Santa Rosa, California, housing six (GMP) suites, two of which are certified as Class 10,000 clean rooms.
The joint venture plans to expand the site by upgrading its existing R&D and analytical capabilities, while adding new capacities, said the company.
Nikolai Sepetov, president and CEO of Nanosyn, said: We are excited to offer this suite of cGMP solutions as a result of this partnership. For our clients, this is a natural extension of Nanosyn’s highly successful discovery services into process development, scale-up, and supply of preclinical and cGMP clinical trial quantities of APIs.